Alpelisib challenge test for body weight study
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a single dose of a drug called alpelisib to see how it affects body weight and metabolism. It may help researchers understand how the drug could be used for weight-related conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a BMI between 18 and 45 (lower for Asian ancestry).
- You must be willing to fast for up to 18 hours and stay in bed for up to 15 hours during the study.
- You must not have diabetes, heart disease, liver disease, or other serious health conditions.
- You must be able to understand English or Spanish.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
This study tests a new way to measure how the body handles insulin in people with different body weights. It may help researchers understand insulin resistance better.
This early study tests whether adding pioglitazone, along with close blood-sugar (glucose/insulin) monitoring, can help control high insulin and high blood sugar in people starting alpelisib for metastatic breast cancer. It may help reduce blood-sugar side effects from alpelisib.
This study tests a new daily pill (aleniglipron) to help adults with excess weight and type 2 diabetes lose weight and improve blood sugar control. It may be a good fit if you have a BMI of 27 or higher and your diabetes is managed with A1c between 6.5% and 10%.
This Phase 1 trial tests a new medicine called ALN-6222 in people with obesity to see if it's safe and how well it works. The study focuses on adults with a BMI between 30 and 40 who don't have diabetes.
This trial tests a drug called alpelisib for children and adults with a rare overgrowth condition called PROS that is caused by a PIK3CA gene change. It aims to see if the drug can safely shrink overgrowth and improve symptoms.
Hear when a new Insulin Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.